Imrich Blasko

Summary

Affiliation: Innsbruck Medical University
Country: Austria

Publications

  1. ncbi request reprint Role of the immune system in the pathogenesis, prevention and treatment of Alzheimer's disease
    Imrich Blasko
    Department of Psychiatry, University Hospital of Innsbruck, Austria
    Drugs Aging 20:101-13. 2003
  2. doi request reprint Conversion from mild cognitive impairment to dementia: influence of folic acid and vitamin B12 use in the VITA cohort
    I Blasko
    Department of Psychiatry and Psychotherapy, Division of General and Social Psychiatry, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria
    J Nutr Health Aging 16:687-94. 2012
  3. doi request reprint Prospective study on association between plasma amyloid beta-42 and atherosclerotic risk factors
    Imrich Blasko
    Section of Psychiatry and Psychotherapy, Department of General and Social Psychiatry, Innsbruck Medical University, Innsbruck, Austria
    J Neural Transm 118:663-72. 2011
  4. doi request reprint Plasma amyloid beta-42 independently predicts both late-onset depression and Alzheimer disease
    Imrich Blasko
    From the Department of Psychiatry and Psychotherapy, Innsbruck Medical University, Austria
    Am J Geriatr Psychiatry 18:973-82. 2010
  5. ncbi request reprint Effects of medications on plasma amyloid beta (Abeta) 42: longitudinal data from the VITA cohort
    Imrich Blasko
    Department of Psychiatry, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria
    J Psychiatr Res 42:946-55. 2008
  6. ncbi request reprint Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine
    Imrich Blasko
    Department of Psychiatry, Innsbruck Medical University, Austria
    Neurobiol Aging 29:1-11. 2008
  7. ncbi request reprint Plasma amyloid beta protein 42 in non-demented persons aged 75 years: effects of concomitant medication and medial temporal lobe atrophy
    Imrich Blasko
    Department of Psychiatry, Innsbruck Medical University, Austria
    Neurobiol Aging 26:1135-43. 2005
  8. doi request reprint Analysis of cerebrospinal fluid of Alzheimer patients. Biomarkers and toxic properties
    Josef Marksteiner
    Department of General Psychiatry, Innsbruck Medical University, Innsbruck, Austria
    Pharmacology 82:214-20. 2008
  9. ncbi request reprint Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias
    Imrich Blasko
    Department of Psychiatry, Innsbruck Medical University, Innsbruck, Austria
    Dement Geriatr Cogn Disord 21:9-15. 2006
  10. ncbi request reprint Cognitive deterioration in Alzheimer's disease is accompanied by increase of plasma neopterin
    Imrich Blasko
    Department of Psychiatry, Innsbruck Medical University, Anichstrasse 35, A 6020 Innsbruck, Tyrol, Austria
    J Psychiatr Res 41:694-701. 2007

Detail Information

Publications13

  1. ncbi request reprint Role of the immune system in the pathogenesis, prevention and treatment of Alzheimer's disease
    Imrich Blasko
    Department of Psychiatry, University Hospital of Innsbruck, Austria
    Drugs Aging 20:101-13. 2003
    ..As adaptive immunity decreases with aging while innate immunity remains intact, immunotherapy for AD will have to be adapted to this situation. Strategies that combine vaccination and inflammatory drug treatment could be considered...
  2. doi request reprint Conversion from mild cognitive impairment to dementia: influence of folic acid and vitamin B12 use in the VITA cohort
    I Blasko
    Department of Psychiatry and Psychotherapy, Division of General and Social Psychiatry, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria
    J Nutr Health Aging 16:687-94. 2012
    ..This study examined the influence of vitamin B12/folic acid intake on the conversion from mild cognitive impairment (MCI) to dementia...
  3. doi request reprint Prospective study on association between plasma amyloid beta-42 and atherosclerotic risk factors
    Imrich Blasko
    Section of Psychiatry and Psychotherapy, Department of General and Social Psychiatry, Innsbruck Medical University, Innsbruck, Austria
    J Neural Transm 118:663-72. 2011
    ..The association of vascular risk factors TC, LDL-C, and HbA1c with higher Aβ42 levels might, after confirmation in other cohorts, influence the development of lifestyle interventions concerning plasma Aβ42 and AD...
  4. doi request reprint Plasma amyloid beta-42 independently predicts both late-onset depression and Alzheimer disease
    Imrich Blasko
    From the Department of Psychiatry and Psychotherapy, Innsbruck Medical University, Austria
    Am J Geriatr Psychiatry 18:973-82. 2010
    ..This study examined the association of emerging late-onset depression (LOD) and AD with plasma Aβ42 in a sample of never depressed and not demented persons at baseline...
  5. ncbi request reprint Effects of medications on plasma amyloid beta (Abeta) 42: longitudinal data from the VITA cohort
    Imrich Blasko
    Department of Psychiatry, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria
    J Psychiatr Res 42:946-55. 2008
    ..Whether the use of gingko biloba might prevent the conversion to MCI or AD needs to be proven in prospective, clinical trials...
  6. ncbi request reprint Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine
    Imrich Blasko
    Department of Psychiatry, Innsbruck Medical University, Austria
    Neurobiol Aging 29:1-11. 2008
    ....
  7. ncbi request reprint Plasma amyloid beta protein 42 in non-demented persons aged 75 years: effects of concomitant medication and medial temporal lobe atrophy
    Imrich Blasko
    Department of Psychiatry, Innsbruck Medical University, Austria
    Neurobiol Aging 26:1135-43. 2005
    ..Considering the increase of Abeta42 plasma levels as a risk factor for AD, any changes induced by medication by long-term use in the peripheral and possibly also in the central compartment, could be of clinical relevance...
  8. doi request reprint Analysis of cerebrospinal fluid of Alzheimer patients. Biomarkers and toxic properties
    Josef Marksteiner
    Department of General Psychiatry, Innsbruck Medical University, Innsbruck, Austria
    Pharmacology 82:214-20. 2008
    ..We conclude that in CSF of AD patients (at least partly) mature NGF-like immunoreactivity is enhanced, and is masked in a bioassay by the toxic properties of CSF...
  9. ncbi request reprint Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias
    Imrich Blasko
    Department of Psychiatry, Innsbruck Medical University, Innsbruck, Austria
    Dement Geriatr Cogn Disord 21:9-15. 2006
    ..It is suggested that the increase in NGF depends on the extent of neurodegeneration of the AD type and the increase in MCP-1 on age...
  10. ncbi request reprint Cognitive deterioration in Alzheimer's disease is accompanied by increase of plasma neopterin
    Imrich Blasko
    Department of Psychiatry, Innsbruck Medical University, Anichstrasse 35, A 6020 Innsbruck, Tyrol, Austria
    J Psychiatr Res 41:694-701. 2007
    ..In summary, neopterin concentrations correlated with cognitive decline in AD patients, which might be due to high CMV seropositivity in that population...
  11. ncbi request reprint How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes
    Imrich Blasko
    Department of Psychiatry, University Hospital of Innsbruck, Innsbruck, Austria
    Aging Cell 3:169-76. 2004
    ..A disturbed balance between the production and the degradation of A beta can trigger chronic inflammatory processes in microglial cells and astrocytes and thus initiate a vicious circle. This leads to a perpetuation of the disease...
  12. doi request reprint Treatment patterns in inpatients with bipolar disorder at a psychiatric university hospital over a 9-year period: focus on mood stabilizers
    Michaela Walpoth-Niederwanger
    Department of Psychiatry and Psychotherapy, Innsbruck Medical University, Innsbruck, Austria
    Int Clin Psychopharmacol 27:256-66. 2012
    ..Clinical decision making, usually made on the basis of individual clinical experience, should always be reevaluated using periodically updated evidence-based medicine guidelines...
  13. ncbi request reprint Efficacy of donepezil treatment in Alzheimer patients with and without subcortical vascular lesions
    Imrich Blasko
    Department of Psychiatry, University Hospital of Innsbruck, Austria
    Pharmacology 72:1-5. 2004
    ..These data support previous observations that donepezil therapy is effective in AD patients with and without subcortical vascular lesions...